Why RWE programs fail under regulatory scrutiny — and what leaders can do about it
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
by: Alexandra Miller, MPH Human papillomavirus (HPV) is one of the most common sexually...
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Early signals indicate continued declines in influenza vaccination uptake and shifts in the...
Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought...
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
AI agents are quickly becoming part of the clinical conversation. Since the release of large...
Recently, Omada Health and HealthVerity announced a press release highlighting their collaboration...
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically, w...